Vical Presents Pandemic Influenza Vaccine Results and Outlook At WHO Meeting
February 13, 2009 06:30 ET
|
Vical Incorporated
GENEVA, Feb. 13, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today presented to the world's leading pandemic influenza vaccine experts a summary of complete results from the company's...
Vical Receives $2.3 Million Payment for Continued Funding of Allovectin-7(r) Phase 3 Trial
February 11, 2009 06:30 ET
|
Vical Incorporated
SAN DIEGO, Feb. 11, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced the receipt of a $2.3 million cash payment from AnGes MG, Inc., related to continued progress in the...
Vical Announces News Release and Conference Call Schedule for 2008 Financial Results
February 10, 2009 06:30 ET
|
Vical Incorporated
SAN DIEGO, Feb. 10, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months and twelve months ended December 31,...
Vical Announces Issuance of U.S. Patent No. 7,470,675 for Composition, Delivery and Use of Gene-Based Interferon-Omega
January 14, 2009 06:30 ET
|
Vical Incorporated
SAN DIEGO, Jan. 14, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today the issuance of U.S. Patent No. 7,470,675 covering the composition, delivery and use of gene-based...